Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 32Carcinoma, Non-Small-Cell Lung 29Neoplasms 26Head and Neck Neoplasms 26Colonic Neoplasms 20Neoplasm Metastasis 17Rectal Neoplasms 12Breast Neoplasms 11Lung Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Squamous Cell 6Tongue Neoplasms 5Salivary Gland Neoplasms 5Melanoma 5Stomach Neoplasms 4Solid Tumors 4Ovarian Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumor 4Triple Negative Breast Neoplasms 3Sarcoma 3Kidney Neoplasms 3Endometrial Neoplasms 3Advanced Cancers 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Recurrence 2Pharyngeal Neoplasms 2Neoplasms by Site 2

Interventions

pembrolizumab 1Poly I-C 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Recurrence, Local × Cetuximab × Clear all
NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago

Phase 1 Recruiting
36 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡